P-GLYCOPROTEIN SYSTEM AS A DETERMINANT OF DRUG INTERACTIONS: THE CASE OF DIGOXIN–VERAPAMIL
- 1 October 1999
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 40 (4) , 301-306
- https://doi.org/10.1006/phrs.1999.0535
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Using the right drug: A treatment algorithm for atrial fibrillationEuropean Heart Journal, 1997
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- MDR Expression in Normal Tissues: Pharmocologic Implication for the Clinical Use of P-Glycoprotein InhibitorsHematology/Oncology Clinics of North America, 1995
- P-glycoprotein-mediated renal tubular secretion of digoxin: The toxicological significance of the urine-blood barrier modelLife Sciences, 1993
- The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1)Life Sciences, 1993
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987
- Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cellsCell, 1986
- Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteinsCell, 1986
- Digoxin-verapamil interactionClinical Pharmacology & Therapeutics, 1981